Why CSL shares could be dirt cheap in 2025

Goldman Sachs sees a lot of value in this blue chip stock.

| More on:
A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Now could be the time to pounce on CSL Ltd (ASX: CSL) shares.

That's the view of analysts at Goldman Sachs, which have just initiated coverage on the company.

CSL is a global biotechnology company with a world-class portfolio of therapies. This includes therapies that treat immune deficiencies, haemophilia, other rare diseases, vaccines to prevent influenza, and therapies in iron deficiency and nephrology.

What is the broker saying about CSL shares?

According to the note, the broker acknowledges that recent times have been challenging for the company and this has weighed on its shares. It said:

The last five years have been particularly challenging for CSL, with the business navigating material inflationary pressures to its plasma collections costs, the threat of a new entrant (anti-FcRn) in its core Immunoglobulin (IG) market, its Vifor acquisition encountering the entry of generics quicker than anticipated and late-stage R&D setbacks.

However, Goldman believes that work behind the scenes with its key IG business has set CSL up for growth. It adds:

Whilst some of these developments have led to structural changes to CSL's business, we believe the company's proactive investments in its IG franchise and new product launches in the Behring portfolio are set to increase ROIC in this new operating environment.

Initiated with a buy rating

The note reveals that Goldman Sachs has initiated coverage with a buy rating. This is based on its belief that IG sales will grow in the double digits through to FY 2028 and underpin margin improvements and strong earnings growth. It said:

Our Buy thesis is driven by (1) Double digit IG growth (GSe: +12.6% FY23-FY28E CAGR) underpinned by low penetration (including CIDP) and ~100bps YoY market share gains. Our channel checks indicate CSL's competitive advantages are intact, with the expansion in fractionation capacity set to enhance CSL's superior cost profile and supply reliability, (2) Strong Gross Margin (GM%) recovery with Behring plasma collection costs per liter set to meaningfully decline (-14.6% FY26E vs FY24), and (3) Rebound in Seqirus growth from depressed US influenza vaccination rates.

Goldman has a buy rating and $325.40 price target on CSL's shares. Based on its current share price of $275.61, this implies potential upside of 18% for investors over the next 12 months. It also expects a modest 1.8% dividend yield in FY 2025, which boosts the total potential return to almost 20%.

Overall, the broker feels that CSL's shares are cheap and a re-rating could be on the way. The broker concludes:

We adopt a premium of 1.8x as part of our valuation which is close to the 10-year average noting the current share price values the business cheaper relative to its 5 and 10-year averages. We believe ongoing momentum in CSL's IG revenue growth, Gross Margin recovery and execution on market share initiatives in Hemophilia and HAE are key drivers in driving re-rating.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »